Nuformix operations are managed by a leadership team and Board with extensive industry experience
Tim Metcalfe, Non-Executive Chairman
Tim is a highly experienced corporate financier and company adviser, having spent over 30 years in a variety of senior City and corporate roles. He has held senior positions at Robert Fleming, Rothschild, Westhouse Securities, Northland Capital Partners and he was Joint CEO of Zeus Capital, prior to co-founding IFC Advisory, an investor relations and financial PR adviser, in 2015. During his career, Tim has had a particular focus on advising companies on strategy, M&A, capital markets and regulatory matters.
In addition to his role as Managing Director of IFC Advisory, Tim is Senior Independent Non-Executive Director of The Investment Company plc, an investment trust listed on the Main Market of the London Stock Exchange, and Non-Executive Chairman of Equipmake Holdings plc, which is listed on Aquis. He is also a director of a number of private companies.
Maddy Kennedy, Non-Executive Director
Maddy Kennedy, FCCA, specialises in growing life science businesses and has more than 20 years of experience in the sector, both in public and private companies.
Maddy runs a CFO portfolio through CFO4Growth and is currently Chief Financial Officer at Arquer Diagnostics and Tetris Pharma. Her previous contracts include being CFO for MyHealthChecked plc, Ieso Digital Health Ltd and PsiOxus Therapeutics Ltd. She was CFO for Lab21 Limited and Finance Director at Alliance Pharma plc, taking it through its IPO.
Committees: Maddy is Chairman of the Audit Committee and a member of the Nomination and Remuneration Committees.
Dr Dan Gooding, Executive Director
Dr Dan Gooding was a co-founder of Nuformix and the Company’s CEO until June 2020. He was reappointed as an Executive Director in July 2022. He instigated the Company’s NXP002 programme as an inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and has over 22 years’ experience in commercialisation and business development within the pharmaceutical industry, having received his PhD in chemistry from Leeds University.
Dan began his career in commercial roles with pharmaceutical excipients companies including FMC and Dow Corning. At Accelrys Ltd, Dan was responsible for sales across the UK and Southern Europe, leading business development within the emerging nanotechnology, drug delivery and formulation sectors, achieving licensing deals with Johnson & Johnson and AstraZeneca. Since June 2020, Dan has remained close to the fields of fibrosis, oncology and drug repurposing. Dan supported the management team of Qureight Limited in securing funding and establishing this Cambridge-based start-up, which develops AI-based image processing methods in measuring disease progression and drug response for patients with fibrotic lung diseases including IPF. Dan has also cofounded TRx Biosciences, a company developing new oral therapies using a novel targeted delivery technology to improve treatment of various cancers and CNS diseases.